keyword
MENU ▼
Read by QxMD icon Read
search

primary hypercholesterolemia

keyword
https://www.readbyqxmd.com/read/28810550/2d-sti-combined-with-gated-99-tc-m-mibi-mpi-for-the-diagnosis-of-myocardial-ischemia-in-hypercholesterolemia-patients
#1
Yi Song, Rui-Fang Zhang, Yu Liu
This study aimed to investigate the reliability of ultrasound two-dimensional speckle tracking imaging (2D-STI) for the evaluation of myocardial ischemia in familial hypercholesterolemia (FH) patients. We recruited 28 patients clinically diagnosed with homozygous familial hypercholesterolemia (HoFH) and subjected them to 2D-STI, gated transthoracic Doppler echocardiography (TTDE), and (99)Tc(m)-methoxyisobutylisonitrile myocardial perfusion imaging ((99)Tc(m)-MIBI MPI). The sensitivity, specificity and diagnostic accordance rate of TTDE and 2D-STI for myocardial ischemia in HoFH patients were compared with the (99)Tc(m)-MIBI scores...
August 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28807459/rapidly-progressive-atherosclerosis-after-domino-liver-transplantation-from-a-teenage-donor-with-homozygous-familial-hypercholesterolemia
#2
Jessica R Golbus, Linda Farhat, Robert J Fontana, Melvyn Rubenfire
Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by impaired clearance of low-density lipoprotein cholesterol. Given limitations in pharmacologic therapy and the significant morbidity and mortality associated with this disease, liver transplantation may be offered to select homozygous FH patients in childhood in an effort to slow progression of atherosclerotic cardiovascular disease. In rare cases, domino liver transplantation can be performed, transplanting the livers of patients with various metabolic disorders into elderly recipients whose projected survival precludes prolonged waiting on the transplant list...
July 22, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28792952/everolimus-long-term-use-in-patients-with-tuberous-sclerosis-complex-four-year-update-of-the-exist-2-study
#3
John J Bissler, J Chris Kingswood, Elzbieta Radzikowska, Bernard A Zonnenberg, Elena Belousova, Michael D Frost, Matthias Sauter, Susanne Brakemeier, Petrus J de Vries, Noah Berkowitz, Maurizio Voi, Severine Peyrard, Klemens Budde
OBJECTIVES: We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. METHODS: Following favorable results from the double-blind core phase of EXIST-2 (NCT00790400), patients were allowed to receive open-label everolimus (extension phase). Patients initially randomly assigned to everolimus continued on the same dose; those who were receiving placebo crossed over to everolimus 10 mg/day...
2017: PloS One
https://www.readbyqxmd.com/read/28768921/efficacy-and-safety-of-the-cholesteryl-ester-transfer-protein-inhibitor-evacetrapib-in-combination-with-atorvastatin-in-japanese-patients-with-primary-hypercholesterolemia
#4
Tamio Teramoto, Arihiro Kiyosue, Takeshi Iimura, Yasushi Takita, Jeffrey S Riesmeyer, Masahiro Murakami
BACKGROUND: Inhibition of cholesteryl ester transfer protein by evacetrapib when added to atorvastatin may provide an additional treatment option for patients who do not reach their low-density lipoprotein cholesterol (LDL-C) goal.Methods and Results:This multicenter, randomized, 12-week, double-blind, parallel-group, placebo-controlled, outpatient, phase 3 study evaluated the efficacy of evacetrapib with atorvastatin in reducing LDL-C in 149 Japanese patients (evacetrapib/atorvastatin, n=53; ezetimibe/atorvastatin, n=50; placebo/atorvastatin, n=46) with primary hypercholesterolemia...
August 3, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28765036/world-heart-federation-cholesterol-roadmap
#5
Adrianna Murphy, Jose R Faria-Neto, Khalid Al-Rasadi, Dirk Blom, Alberico Catapano, Ada Cuevas, Francisco Lopez-Jimenez, Pablo Perel, Raul Santos, Allan Sniderman, Rody Sy, Gerald F Watts, Dong Zhao, Salim Yusuf, David Wood
BACKGROUND: The World Heart Federation has undertaken an initiative to develop a series of Roadmaps. OBJECTIVES: The aim of these is to promote development of national policies and health systems approaches and identify potential roadblocks on the road to effective prevention, detection and management of cardiovascular disease (CVD) in low-and middle-income countries (LMIC), and strategies for overcoming these. This Roadmap focuses on elevated blood cholesterol, a leading risk factor for myocardial infarction, stroke, and peripheral arterial disease...
July 29, 2017: Global Heart
https://www.readbyqxmd.com/read/28762942/-recommendations-of-the-european-society-of-cardiology-and-the-european-atherosclerosis-society-on-cardiovascular-disease-prevention-and-management-of-dyslipidemias-for-the-diagnosis-of-atherosclerosis-and-dyslipidemia-treatment-2016-basic-s-g
#6
M G Bubnova, V V Kukharchuk
This review summarizes the main provisions of the new, issued in 2016, recommendations of the European Society of Cardiology and Atherosclerosis Society in cooperation with the European Association on Cardiovascular Prevention and Rehabilitation on Cardiovascular disease prevention and Management of dyslipidemia. In these recommendations, the following trends can be traced distinctly: priority in primary prevention is given to non-drug methods of influence; targets of hypolipidemic therapy are identified not only for low density lipoprotein (LDL) cholesterol (CH), but also for non-high density lipoprotein (HDL) CH, especially in cases of concomitant hypertriglyceridemia...
March 2017: Kardiologiia
https://www.readbyqxmd.com/read/28752495/changing-clinical-phenotypes-of-hiv-associated-neurocognitive-disorders
#7
Ned Sacktor
HIV-associated neurocognitive disorder (HAND) remains a common cause of cognitive impairment and persists in 15-55% of HIV+ individuals in the combination antiretroviral therapy (CART) era. CART is now the primary treatment for HAND, but it is effective in only a subset of patients. In the pre-CART era, HIV-associated dementia was the most common form of HAND. However, in CART-treated patients, the prevalence of HIV-associated dementia has declined substantially, and milder stages of HAND, i.e., ANI and MND predominate...
July 27, 2017: Journal of Neurovirology
https://www.readbyqxmd.com/read/28744105/pattern-of-statin-use-changes-following-media-coverage-of-its-side-effects
#8
Margit Kriegbaum, Kasper Bering Liisberg, Helle Wallach-Kildemoes
BACKGROUND: The media plays a role in shaping opinions about medical decisions, for example, whether to initiate or stop treatment. An association between negative media attention and statin discontinuation has been demonstrated, but it may differ depending on the reason for prescription and whether the user is new (incident) or long term (prevalent). AIM: The aim of this study is to explore whether a Danish newspaper article featuring the side effects of statins affects statin discontinuation in incident versus prevalent users, with the reason for prescription also taken into account...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28712132/impact-of-lipoprotein-apheresis-with-dextran-sulfate-adsorption-on-the-expression-of-genes-involved-in-cardiovascular-health-in-the-blood-of-patients-with-homozygous-familial-hypercholesterolemia
#9
Jean-Philippe Drouin-Chartier, André J Tremblay, Jean Bergeron, Nathalie Laflamme, Benoît Lamarche, Patrick Couture
Lipoprotein apheresis (LA) with dextran sulfate adsorption (DSA) is a reliable method to decrease LDL-cholesterol (C) concentrations in patients with homozygous familial hypercholesterolemia (HoFH). The objective of the present study was to investigate the impact of LA with DSA on the mRNA expression of genes associated with cardiovascular health in the whole blood of HoFH patients. Blood samples were collected before and after LA treatment with DSA in 9 HoFH patients. Microarray analyses were performed to measure the whole blood expression of >30 000 annotated genes pre- and post-LA...
July 16, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28697767/the-impact-of-the-time-of-drug-administration-on-the-effectiveness-of-combined-treatment-of-hypercholesterolemia-with-rosuvastatin-and-ezetimibe-roseze-study-protocol-for-a-randomized-controlled-trial
#10
Karolina Obońska, Michał Kasprzak, Joanna Sikora, Ewa Obońska, Krzysztof Racki, Natalia Goździkiewicz, Magdalena Krintus, Jacek Kubica
BACKGROUND: Hypercholesterolemia is one of the main risk factors for cardiovascular disease. The first line treatment for hypercholesterolemia is statin therapy. When the expected low-density lipoprotein cholesterol (LDL-C) concentration is not achieved, the pharmacotherapy may be extended by combining the statin with the cholesterol absorption inhibitor ezetimibe. METHODS/DESIGN: The study is designed as a randomized, open-label, single-center, crossover study evaluating the effectiveness of combined therapy with rosuvastatin and ezetimibe for hypercholesterolemia...
July 11, 2017: Trials
https://www.readbyqxmd.com/read/28668840/in-vitro-apoptosis-induction-by-fenofibrate-in-lymphoma-and-multiple-myeloma
#11
Leonard Christopher Schmeel, Frederic Carsten Schmeel, Ingo G H Schmidt-Wolf
BACKGROUND/AIM: Recent innovations in the treatment of multiple myeloma have enriched our therapeutic repertoire regarding the treatment of multiple myeloma during the last decades. However, despite today's therapies many multiple myeloma (MM) patients experience relapse of disease and eventually remain incurable. Wnt/β-catenin signaling has been demonstrated in lymphoma and MM, rendering related signaling molecules promising therapeutic targets. Fenofibrate, an extensively scrutinized and widely used drug for primary hypercholesterolemia or mixed dyslipidemia, has proven anticarcinogenic properties mediated by peroxisome proliferator-activated receptor-alpha (PPARα) agonism, thereby also influencing WNT-associated signaling molecules...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28660384/increased-hepatic-abca1-transporter-is-associated-with-hypercholesterolemia-in-a-cholestatic-rat-model-and-primary-biliary-cholangitis-patients
#12
Yasuaki Takeyama, Yuko Uehara, Akira Anan, Daisuke Morihara, Keiji Yokoyama, Kazuhide Takata, Takashi Tanaka, Makoto Irie, Kaoru Iwata, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka
Hepatic ATP-binding cassette A1 (ABCA1) transporter is the modulator of intrahepatic cholesterol levels via the efflux of cholesterol into plasma. This study aimed to determine the expression of hepatic ABCA1 levels in a cholestatic rat model and patients with primary biliary cholangitis (PBC). A cholesterol efflux study was conducted with Abca1 knock down using siRNA in WIF9 cells. Cholesterol levels in the ABCA1 siRNA cells in the medium were significantly decreased compared with those in controls (P < 0...
June 28, 2017: Medical Molecular Morphology
https://www.readbyqxmd.com/read/28655522/preventive-effect-of-pravastatin-on-the-development-of-hypertension-in-patients-with-hypercholesterolemia-a-post-hoc-analysis-of-the-management-of-elevated-cholesterol-in-the-primary-prevention-group-of-adult-japanese-mega-study
#13
Toshiaki Otsuka, Kyoichi Mizuno, Tomohiro Shinozaki, Yuko Kachi, Haruo Nakamura
BACKGROUND: It remains unclear whether treatment of dyslipidemia with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) reduces the risk of developing hypertension. OBJECTIVE: In this post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study, a large-scale primary prevention trial with pravastatin, we examined the preventive effect of pravastatin on the future development of hypertension in patients with hypercholesterolemia...
June 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28652529/efficacy-and-safety-of-cholesteryl-ester-transfer-protein-inhibitor-evacetrapib-administered-as-monotherapy-in-japanese-patients-with-primary-hypercholesterolemia
#14
Tamio Teramoto, Arihiro Kiyosue, Takeshi Iimura, Yasushi Takita, Jeffrey S Riesmeyer, Masahiro Murakami
BACKGROUND: Inhibition of cholesteryl ester transfer protein with evacetrapib may provide an additional treatment option for patients who do not reach their low-density lipoprotein cholesterol (LDL-C) goal with statins or patients who cannot tolerate statins.Methods and Results:This multicenter, randomized, 12-week, double-blind, parallel group, placebo-controlled, outpatient, phase 3 study evaluated the efficacy of evacetrapib in reducing LDL-C in 54 Japanese patients (27 evacetrapib, 27 placebo) with primary hypercholesterolemia...
June 23, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28652386/long-term-cardiovascular-risk-in-heterozygous-familial-hypercholesterolemia-relatives-identified-by-cascade-screening
#15
Kasper Aalbæk Kjærgaard, Morten Krogh Christiansen, Morten Schmidt, Morten Smærup Olsen, Henrik Kjærulf Jensen
BACKGROUND: Heterozygous familial hypercholesterolemia increases the risk of adverse cardiovascular events. Whether affected relatives of probands are at increased risk remains unknown. We aimed to evaluate the long-term cardiovascular risk in heterozygous familial hypercholesterolemia relatives with a low-density lipoprotein receptor (LDLR) mutation who were all recommended statin therapy. METHODS AND RESULTS: Participants were identified by cascade screening at Aarhus University Hospital during 1992-1994...
June 26, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28652127/efficacy-of-a-combined-strategy-to-improve-low-density-lipoprotein-cholesterol-control-among-patients-with-hypercholesterolemia-a-randomized-clinical-trial
#16
Ignacio Párraga-Martínez, Francisco Escobar-Rabadán, Joseba Rabanales-Sotos, Fernando Lago-Deibe, Juan M Téllez-Lapeira, Alejandro Villena-Ferrer, Mariano Blasco-Valle, José M Ferreras-Amez, Susana Morena-Rayo, José M Del Campo-Del Campo, M Candelaria Ayuso-Raya, José J Pérez-Pascual
INTRODUCTION AND OBJECTIVES: Several interventions can improve low-density lipoprotein cholesterol (LDL-C) control. Our main objective was to evaluate the efficacy of a combined intervention to improve LDL-C control in patients with hypercholesterolemia. The study also assessed the efficacy of the intervention in improving adherence (pharmacological, diet, and exercise). METHODS: A multicenter, parallel group, randomized clinical trial (primary care) was conducted in 358 adults diagnosed with hypercholesterolemia, whether receiving prior drug therapy or not...
June 23, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28646901/effect-of-ezetimibe-add-on-therapy-over-52%C3%A2-weeks-extension-analysis-of-prospective-randomized-trial-research-study-in-type-2-diabetes-subjects
#17
Kentaro Sakamoto, Mitsunobu Kawamura, Takayuki Watanabe, Keiko Ashidate, Takahide Kohro, Akira Tanaka, Yasumichi Mori, Motoki Tagami, Tsutomu Hirano, Tsutomu Yamazaki, Teruo Shiba
BACKGROUND: Lowering cholesterol levels decreases the risk of atherosclerotic diseases. Effective ways to stably reduce LDL-C level are warranted in type 2 diabetic patients, a high-risk population for CVD, with various anti-diabetic therapeutic background. The RESEARCH study focuses on LDL-C reduction in this population along with modifications of the lipid profiles. We evaluated long-term ezetimibe add-on therapy in T2DM patients with hypercholesterolemia. METHODS: In a randomized, multicenter, open-label, prospective study, a total of 109 T2DM patients not attaining LDL-C target value despite first-line dose statin (10 mg of atorvastatin or 1 mg of pitavastatin) therapy in Japan were recruited...
June 24, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28643240/pcsk9-inhibitors-treating-the-right-patients-in-daily-practice
#18
REVIEW
Peta King, Stephen J Nicholls
PURPOSE OF REVIEW: Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a novel approach to low-density lipoprotein cholesterol (LDL-C) lowering. The potential role of PCSK9 inhibitors in clinical practice will be reviewed. RECENT FINDINGS: Clinical trials have demonstrated that PCSK9 inhibitors produce robust LDL-C lowering when administered either as monotherapy or in combination with statins. This provides the opportunity to achieve effective lipid lowering in familial hypercholesterolemia, patients with either established atherosclerotic cardiovascular disease or high risk primary prevention and an important opportunity to treat patients with statin intolerance...
August 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28639183/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-its-inhibitors-a-review-of-physiology-biology-and-clinical-data
#19
REVIEW
Ashwin Durairaj, Alberto Sabates, Jonathan Nieves, Brian Moraes, Seth Baum
Atherosclerotic cardiovascular disease (ASCVD) remains the number one killer in the western world. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and ezetimibe has been shown to reduce the risk of cardiovascular events. Now, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mabs) are available for high-risk individuals with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy but requiring greater LDL-C reduction. PCSK9 mab outcome trial results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk (FOURIER) study, which was presented at the American College of Cardiology in March 2017, which demonstrated a decrease of 15% in primary and 20% secondary end points over a 2-year period [1••]...
August 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28627192/-excess-weight-in-patients-with-cystic-fibrosis-is-it-always-beneficial
#20
David González Jiménez, Rosana Muñoz-Codoceo, María Garriga-García, Manuel Molina-Arias, Marina Álvarez-Beltrán, Ruth García-Romero, Cecilia Martínez-Costa, Silvia María Meavilla-Olivas, Luis Rodrigo Peña-Quintana, Silvia Gallego Gutiérrez, José Manuel Marugán de Miguelsanz, Lucrecia Suárez Cortina, Esperanza Natividad Castejón Ponce, Rosaura Leis Trabazo, Fayna Martín Cruz, Juan José Díaz Martín, Carlos Bousoño García
INTRODUCTION: The primary objective of this study was to find out the prevalence of overweight and obese status, as well as their association to pulmonary function, total cholesterol and vitamin D in patients with cystic fibrosis (CF). MATERIALS AND METHODS: This is a multicenter descriptive and cross-sectional study. Twelve Spanish hospitals participated. 451 patients with CF were included. Adults were classified according to body mass index (BMI) and children were classified according to BMI percentiles (WHO tables)...
June 5, 2017: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
keyword
keyword
65021
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"